Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases

Biomaterials

Volumn 34, Issue 15, 2013, Pages 3795-3806

  Miller, Keren ^a   Clementi, Chiara ^b   Polyak, Dina ^a   Eldar Boock, Anat ^a   Benayoun, Liat ^c   Barshack, Iris ^a,d   Shaked, Yuval ^c   Pasut, Gianfranco ^b   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF PADOVA   (Italy)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Alendronate; Angiogenesis; Bone targeting; Dendrimers; PEG; Polymer therapeutics

Indexed keywords

ALENDRONATE; ANGIOGENESIS; ANTI-ANGIOGENIC ACTIVITY; ANTI-ANGIOGENIC THERAPY; BONE TARGETING; FLUORESCENCE IMAGING SYSTEMS; PHARMACOKINETIC PROFILES; POLYMER THERAPEUTICS;

DENDRIMERS; DISEASES; FUNCTIONAL POLYMERS; MICELLES; MOLECULES; PATHOLOGY; POLYETHYLENE GLYCOLS; TUMORS;

BONE;

ALENDRONIC ACID; MACROGOL; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ALENDRONATE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICELLES; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; POLYETHYLENE GLYCOLS; TIBIA; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874963834     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.052     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Demicheli R., Valagussa P., Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases?. Br J Cancer 2001, 85(4):490-492.
3. Hansen E., Wolff N., Knuechel R., Ruschoff J., Hofstaedter F., Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995, 130(4):387-393.
4. Colleoni M., O'Neill A., Goldhirsch A., Gelber R.D., Bonetti M., Thurlimann B., et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000, 18(23):3925-3935.
5. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000, 5(1):75-81.
6. Horwitz S.B., Cohen D., Rao S., Ringel I., Shen H.J., Yang C.P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monographs 1993, 15:55-61.
7. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22(56):9075-9086.
8. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14(1):13-19.
9. Pasquier E., Carre M., Pourroy B., Camoin L., Rebai O., Briand C., et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004, 3(10):1301-1310.
10. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8(7):1263-1268.
11. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37(13):1590-1598.
12. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006, 13(1):7-26.
13. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62(22):6538-6544.
14. Sevcik M.A., Luger N.M., Mach D.B., Sabino M.A., Peters C.M., Ghilardi J.R., et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 2004, 111(1-2):169-180.
15. Wang D., Miller S., Sima M., Kopeckova P., Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003, 14(5):853-859.
16. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002, 8(21):1929-1944.
17. Wang D., Miller S.C., Kopeckova P., Kopecek J. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 2005, 57(7):1049-1076.
18. Hirabayashi H., Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharm 2003, 42(15):1319-1330.
19. Segal E., Pan H., Ofek P., Udagawa T., Kopeckova P., Kopecek J., et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009, 4(4):e5233.
20. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 2009, 48(16):2949-2954.
21. Miller K., Eldar-Boock A., Polyak D., Segal E., Benayoun L., Shaked Y., et al. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharmacol 2011, 8(4):1052-1062.
22. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
23. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009, 61(13):1177-1188.
24. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6(9):688-701.
25. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007, 35(Pt. 1):56-60.
26. Satchi-Fainaro R. Targeting tumor vasculature: reality or a dream?. J Drug Target 2002, 10(7):529-533.
27. Santucci L., Mencarelli A., Renga B., Ceccobelli D., Pasut G., Veronese F.M., et al. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs 2007, 18(9):1081-1091.
28. Pasut G., Greco F., Mero A., Mendichi R., Fante C., Green R.J., et al. Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. J Med Chem 2009, 52(20):6499-6502.
29. Clementi C., Miller K., Mero A., Satchi-Fainaro R., Pasut G. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharmacol 2011, 8(4):1063-1072.
30. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7(1):101-111.
31. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324(1):1-8.
32. Arbuck S.G., Dorr A., Friedman M.A. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 1994, 8(1):121-140.
33. Cetnar J.P., Malkowicz S.B., Palmer S.C., Wein A.J., Vaughn D.J. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer. Urology 2008, 71(5):942-946.
34. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 2006, 17(5):735-749.
35. Sanfilippo N.J., Taneja S.S., Chachoua A., Lepor H., Formenti S.C. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 2008, 26(18):2973-2978.
36. Wang D., Sima M., Mosley R.L., Davda J.P., Tietze N., Miller S.C., et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharmacol 2006, 3(6):717-725.
37. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14(3):263-273.
38. Bertolini F., Mancuso P., Braidotti P., Shaked Y., Kerbel R.S. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim Biophys Acta 2009, 1796(1):27-32.
39. Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6(11):835-845.
40. Mancuso P., Colleoni M., Calleri A., Orlando L., Maisonneuve P., Pruneri G., et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108(2):452-459.
41. Glade Bender J.L., Adamson P.C., Reid J.M., Xu L., Baruchel S., Shaked Y., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008, 26(3):399-405.
42. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26(30):4899-4905.